US Family Health Plan Prior Authorization Request Form for

Testosterone cypionate IM, testosterone enanthate IM, Testosterone enanthate (Xyosted)

To be completed and signed by the prescriber. To be used only for prescriptions which are to be filled through the Department of Defense (DoD) US Family Health Plan Pharmacy Program. US Family Health Plan is a TRICARE contractor for DoD.

The completed form may be faxed to 855-273-5735

OR

The patient may attach the completed form to the prescription and **mail** it to:

Attn: Pharmacy, 77 Warren St, Brighton, MA 02135

QUESTIONS? Call 1-877-880-7007

Prior authorization is not required for patients younger than 1 year of age. Prior authorization for initial therapy expires in 1 year. Prior authorization for continuation of therapy for adults does not expire. Prior authorization for continuation of therapy for children expires in 1 year. Step Please complete patient and physician information (please print): 1 Patient Name: Physician Name: Address: Address: _____ Sponsor ID# Phone #: Date of Birth: Secure Fax #: Please complete the clinical assessment: Step 2 □ No Will the requested medication be used to enhance ☐ Yes athletic performance? **STOP** Proceed to question 2 Coverage not approved Will the requested medication be used concomitantly ☐ Yes □ No with other testosterone products? **STOP** Proceed to question 3 Coverage not approved □ No ☐ Yes Has the patient received this medication under the Proceed to question 6 TRICARE benefit in the last 6 months? Please choose (subject to verification) "No" if the patient did not previously have a TRICARE approved PA for the requested medication. Proceed to question 4 □ No 4. Has the patient had a positive response to therapy? ☐ Yes **STOP** Proceed to question 5

Do the benefits of continued therapy outweigh the

risks?

Coverage not approved

□ No

STOP

Coverage not approved

□ Yes

Sign and date below

US Family Health Plan Prior Authorization Request Form for Testosterone cypionate IM, testosterone enanthate IM, Testosterone enanthate (Xyosted)

6.	Was the patient born a male (natal male, assigned male at birth)?	☐ Yes Proceed to question 7	☐ No Proceed to question 9	
7.	Is the patient 18 years of age or older?	☐ Yes Proceed to question 8	☐ No Proceed to question 10	
8.	What is the diagnosis or indication?	☐ Hypogonadism - Proceed to question 12☐ Other - Proceed to question 29☐		
9.	What is the diagnosis or indication?	□ Female-to-male gender-affirming hormone therapy in a natal female patient (assigned female at birth) - Proceed to question 17 □ Breast cancer - Proceed to question 25 □ Other - Proceed to question 29		
10.	What is the requested medication?	☐ Testosterone cypionate IM- Proceed to question 11☐ Testosterone enanthate IM- Proceed to question 11☐ Xyosted – STOP Coverage not approved		
11.	Is the prescription written by or in consultation with a pediatric endocrinologist or pediatric urologist?	☐ Yes Sign and date below	□ No STOP Coverage not approved	
12.	Does the patient have a confirmed diagnosis of hypogonadism as evidenced by 2 or more morning total serum testosterone levels below 300 ng/dL taken on at least two separate occasions?	☐ Yes Proceed to question 14	☐ No Proceed to question 13	
13.	Is the requested medication prescribed by an endocrinologist or urologist who has made the diagnosis of hypogonadism based on unequivocally and consistently low serum total testosterone or free testosterone levels?	☐ Yes Proceed to question 14	□ No STOP Coverage not approved	
14.	Is the patient experiencing signs and symptoms associated with hypogonadism?	☐ Yes Proceed to question 15	□ No STOP Coverage not approved	
15.	Has the provider investigated the etiology of the low testosterone levels and has assessed the risks versus benefits of initiating testosterone therapy in this patient?	☐ Yes Proceed to question 16	□ No STOP Coverage not approved	
16.	Does the provider acknowledge that testosterone therapy is clinically appropriate and needed?	☐ Yes Proceed to question 26	□ No STOP Coverage not approved	
17.	Is the patient greater than or equal to 14 years of age?	☐ Yes Proceed to question 18	□ No STOP Coverage not approved	

US Family Health Plan Prior Authorization Request Form for Testosterone cypionate IM, testosterone enanthate IM, Testosterone enanthate (Xyosted)

18. Does the patient have a diagnosis of gender dysphoria made by a TRICARE authorized mental health provider according to the most current editior of the Diagnostic and Statistical Manual of Mental Disorders (DSM)?	☐ Yes Proceed to question 19	□ No STOP Coverage not approved
19. Is the prescription written by an endocrinologist or a physician who specializes in the treatment of transgender patients?	☐ Yes Proceed to question 20	□ No STOP Coverage not approved
20. Is the patient an adult, or an adolescent with sufficient mental capacity to give informed consent for this partially irreversible treatment?	☐ Yes Proceed to question 21	□ No STOP Coverage not approved
21. Has the patient experienced puberty to at least Tanner stage 2?	☐ Yes Proceed to question 22	□ No STOP Coverage not approved
22. Is the patient of childbearing potential?	☐ Yes Proceed to question 23	☐ No Proceed to question 24
23. Is the patient pregnant or breastfeeding?	☐ Yes STOP Coverage not approved	☐ No Proceed to question 24
24. Does the patient have a psychiatric comorbidity that would confound a diagnosis of gender dysphoria or interfere with treatment (for example, unresolved body dysmorphic disorder; schizophrenia or other psychotic disorders that have not been stabilized with treatment)?	☐ Yes STOP Coverage not approved	☐ No Proceed to question 26
25. Is the prescription written by or in consultation with an oncologist?	☐ Yes Proceed to question 26	□ No STOP Coverage not approved
26. What is the requested medication?	☐ Testosterone cypionate IM - Sign and date below ☐ Testosterone enanthate IM - Sign and date below ☐ Xyosted - Proceed to question 27	
27. Has the patient tried and failed a 3 month trial of one drug from each of the following two categories: (1) Testosterone cypionate IM injection or Testosterone enanthate IM injection; (2) Testosterone 1% gel (for example, generic Androgel, generic Testim), 1.62% gel (generic Androgel), or 2% solution (generic Axiron)?	☐ Yes Sign and date below	☐ No Proceed to question 28

US Family Health Plan Prior Authorization Request Form for Testosterone cypionate IM, testosterone enanthate IM, Testosterone enanthate (Xyosted)

	28.	Has the patient experienced a clinically significant adverse reaction, or had a contraindication or relative contraindication to one drug from each of the following two categories: (1) Testosterone cypionate IM injection or Testosterone enanthate IM injection; (2) Testosterone 1% gel (for example, generic Androgel, generic Testim), 1.62% gel (generic Androgel), or 2% solution (generic Axiron)?	☐ Yes Sign and date below	□ No STOP Coverage not approved
	29.	If the indication is not listed above, please write in requested indication and rationale for use.	Proceed to question 30	
	30.	What is the requested medication?	☐ Testosterone cypionate IM - Sign and date below ☐ Testosterone enanthate IM - Sign and date below ☐ Xyosted - Proceed to question 31	
	31.	Has the patient tried and failed a 3 month trial of one drug from each of the following two categories: (1) Testosterone cypionate IM injection or Testosterone enanthate IM injection; (2) Testosterone 1% gel (for example, generic Androgel, generic Testim), 1.62% gel (generic Androgel), or 2% solution (generic Axiron)?	☐ Yes Sign and date below	☐ No Proceed to question 32
	32.	Has the patient experienced a clinically significant adverse reaction, or had a contraindication or relative contraindication to one drug from each of the following two categories: (1) Testosterone cypionate IM injection or Testosterone enanthate IM injection; (2) Testosterone 1% gel (for example, generic Androgel, generic Testim), 1.62% gel (generic Androgel), or 2% solution (generic Axiron)?	☐ Yes Sign and date below	□ No STOP Coverage not approved
Step 3	I certify the above is true to the best of my knowledge. Please sign and date:			
		Prescriber Signature	Date	

[29 May 2024]